1. Multivalent γ-PGA-Exendin-4 Conjugates to Target Pancreatic β-Cells
- Author
-
Lorenzo Rossi, Krisztina Kerekes, Judit Kovács‐Kocsi, Zoltán Körhegyi, Magdolna Bodnár, Erika Fazekas, Eszter Prépost, Cataldo Pignatelli, Enrico Caneva, Francesco Nicotra, Laura Russo, Rossi, L, Kerekes, K, Kovacs-Kocsi, J, Korhegyi, Z, Bodnar, M, Fazekas, E, Prepost, E, Pignatelli, C, Caneva, E, Nicotra, F, and Russo, L
- Subjects
Organic Chemistry ,poly-gamma-glutamic acid ,Glutamic Acid ,beta-cell targeting ,Biochemistry ,Glucagon-Like Peptide-1 Receptor ,Pancreatic Neoplasms ,Diabetes Mellitus, Type 2 ,Polyglutamic Acid ,diabete ,exendin-4 ,Exenatide ,Humans ,Molecular Medicine ,pancreatic tumor ,Radiopharmaceuticals ,Peptides ,Molecular Biology ,GLP-1R - Abstract
Targeting of glucagon-like peptide 1 receptor (GLP-1R), expressed on the surface of pancreatic β-cells, is of great interest for the development of advanced therapies for diabetes and diagnostics for insulinoma. We report the conjugation of exendin-4 (Ex-4), an approved drug to treat type 2 diabetes, to poly-γ-glutamic acid (γ-PGA) to obtain more stable and effective GLP-1R ligands. Exendin-4 modified at Lysine-27 with PEG4-maleimide was conjugated to γ-PGA functionalized with furan, in different molar ratios, exploiting a chemoselective Diels-Alder cycloaddition. The γ-PGA presenting the highest number of conjugated Ex-4 molecules (average 120 per polymeric chain) showed a double affinity towards GLP-1R with respect to exendin per se, paving the way to improved therapeutic and diagnostic applications.
- Published
- 2022